Pete, not arguing, but $50 for Kevetrin in Phase 2 (not yet complete) is pure fantasy. Successful Phase 1 is a low bar . . . real price appreciation is not going to take place until Phase 3 and approval. That's where the real risk is and that is what big pharma can assume, CTIX can't. Frankly, I would love to see $2 before we here any more about outlandish buyout prices.